Overview

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
0
Participant gender:
Female
Summary
Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology
North Eastern Germany Society of Gynaecologic Oncology
Treatments:
Topotecan
Criteria
Inclusion Criteria:

- patients with histologically-confirmed ovarian cancer

- relapse within 6 month after primary therapy

- primary therapy with platin and taxan

- ECOG 0-2

- >= 18 years

- leukocytes >= 3.000/ µl

- platelet >= 100.000/ µl

- neutrophil >= 1.500/ µl

- written informed consent

Exclusion Criteria:

- earlier topotecan therapy

- simultaneous or planned radiotherapy

- secondary malignancy